Latest from Siteman

Physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $7.8 million grant from the National Cancer Institute to play a leading role in designing, conducting and enrolling patients in clinical trials through the NCI
Brian A. Van Tine, MD, PhD, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.
Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.
Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).
Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.
Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.
Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).
Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.
Publication Bottom Border
Border Publication
x